Browsing by Author Central Clinical School: The Sydney Cancer Centre

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 21 to 40 of 124 < previous   next >
Issue DateTitleAuthor(s)Citation
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2015Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dummer, R; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Larkin, James; Schadendorf, Dirk; Smylie, Michael; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England Journal of Medicine, vol.373, 1, 2015,pp 23-34
2015Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialLong, Georgina; Amonkar, Mayur M; Drucis, Kamil; Dummer, R; et al, Various; Grange, Florent; Grob, Jean Jacques; Karaszewska, Boguslawa; Mackiewicz, Andrzej; Schachter, Jacob; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreComparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial, The Lancet Oncology, vol.16, 13, 2015,pp 1389-1398
2016Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision makingKakavand, Hojabr; Long, Georgina; Mann, Graham; Menzies, Alexander Maxwel; Pupo, Gulietta; Scolyer, Richard; Wilmott, James; De Paoli-Iseppi, Ricardo; Dias, Kerith-Rae; Dinger, Marcel; Hayward, Nicholas K; Johansson, Peter; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Central Clinical School: Pathology; Central Clinical School: SurgeryComparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making, Pathology, vol.48, 3, 2016,pp 261-266
2014Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomasKakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; O'Toole, Sandra; Scolyer, Richard; Thompson, John; Wilmott, James; Crainic, Oana; Lum, Trina; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryConcordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas, Pathology, vol.46, 3, 2014,pp 193-198
2014Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanomaCarlino, Matteo; Hamilton, Anne; Haydu, Lauren; Kakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; O'Toole, Sandra; Scolyer, Richard; Thompson, John; Yu, Bing; Cooper, Wendy; Ng, C; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: MedicineCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma, British Journal of Cancer, vol.111, 2, 2014,pp 292-299
2016Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trialsKefford, Richard (Rick); Long, Georgina; Carver, Jennifer; Casey, Michelle; Flaherty, Keith; Gagnon, Robert; Goodman, Vicki; Haney, Patricia; Hauschild, Axel; Hwu, Patrick; Legos, Jeffrey J.; Martin, Anne-Marie; Mazumdar, Jolly; O'Hagan, Anne; Santiago-Walker, Ademi; Schadendorf, D; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreCorrelation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials, Clinical Cancer Research, vol.22, 3, 2016,pp 567-574
2012Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic MelanomaAnforth, Rachael; Fernandez-Penas, Pablo; Kefford, Richard (Rick); Long, Georgina; Scolyer, Richard; Blumetti, Tatiana Cristina Moraes Pinto; Kossard, Steven; Sharma, Raghwa; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyCutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma, British Journal of Dermatology, vol.167, 5, 2012,pp 1153-1160
2013Cutaneous toxicities of RAF inhibitorsAnforth, Rachael; Fernandez-Penas, Pablo; Long, Georgina; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreCutaneous toxicities of RAF inhibitors, Lancet Oncology, vol.14, 1, 2013,pp e11-e18
2007Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma expleomorphic adenoma of the parotid glandFredericks, S; Gao, K; Hughes, Clifford; Lee, Cheok; O'Brien, Christopher; Patel, Rakesh; Rose, Barbara; Smith, Garett; Hong, A.; Central Clinical School: Pathology; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Surgery; Central Clinical School: Medicine; Central Clinical School: Surgery; Medicine; Central Clinical School: Medicine; SurgeryCyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma expleomorphic adenoma of the parotid gland, Histopathology, vol.51,(1),2007,pp 21-25
2007Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid glandBawdon, H; Fredericks, S; Gao, K; Hong, Angela; Lee, Cheok; O'Brien, Christopher; Patel, Rajan; Rose, Barbara; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Pathology; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Medicine; Central Clinical School: MedicineCyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland, Histopathology, vol.51,(5),2007,pp 691-696
2008Cytosolic PhospholipaseA2-A: A Potential Therapeutic Target for Prostate CancerDong, Qihan; King, Nicholas; Kurek, Caroline; Lu, Sasa; Niknami, Marzieh; Patel, Manish; Singh, Jaskirat; Yao, Mu; Boulas, John; Gelb, Micheal H; Maclean, Fiona; Russell, Pamela J.; Scott, Kieran F; Central Clinical School: Medicine; School of Medical Sciences: Pathology; Medicine; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Western Clinical School: Surgery; Central Clinical School: Office; Central Clinical School: MedicineCytosolic PhospholipaseA2-A: A Potential Therapeutic Target for Prostate Cancer, Clinical Cancer Research, vol.14, 24, 2008,pp 8070-8079
2012Dabrafenib and its potential for the treatment of metastatic melanomaLong, Georgina; Menzies, Alexander; Murali, Rajmohan; Central Clinical School: The Sydney Cancer CentreDabrafenib and its potential for the treatment of metastatic melanoma, Drug Design, Development and Therapy, vol.6, N/A, 2012,pp 391-405
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2014Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic MelanomaLong, Georgina; Menzies, Alexander Maxwel; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineDabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma, Clinical Cancer Research, vol.20, 8, 2014,pp 2035-2043
2012Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialKefford, Richard (Rick); Long, Georgina; Arkenau, Tobias; Brown, Michael P.; et al, various; Falchook, GErald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; O'Day, Steven; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, 9829, 2012,pp 1893-1901
2012Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialKefford, Richard (Rick); Long, Georgina; Algazi, Alain; Ascierto, Paolo; Chapman, Paul; Davies, Michael; et al, Various; Hauschild, A; Mortier, Laurent; Puzanov, Igor; Robert, C; Tawbi, Hussein; Trefzer, Uwe; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, The Lancet Oncology, vol.13, 11, 2012,pp 1087-1095
2014Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up StudyCoates, Elliot; Guitera, Pascale Andree; Haass, Nikolas; Ho, Kenneth; Mann, Graham; Menzies, Scott; Moloney, Fergal; O'Connell, Rachel; Schmid, Helen; Khoury, Ritta; Raudonikis, Leo; Central Clinical School: Medicine; Central Clinical School: Sydney Melanoma Unit; Central Clinical School: Centenary Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Medicine; Dermatology Research Foundat.; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Detection of Primary Melanoma in Individuals at Extreme High Risk: A Prospective 5-year Follow-up Study, JAMA Dermatology, vol.150, 8, 2014,pp 819-827
2014Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanomaCarlino, Matteo; Fung, C.; Gowrishankar, Kavitha; Hersey, Peter; Kefford, Richard (Rick); Long, Georgina; Mijatov, Branka; Pupo, Gulietta; Rizos, Helen; Snoyman, Stephanie; Todd, Jason; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteDifferential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma, Molecular Oncology, vol.8, 3, 2014,pp 544-554